SEC Form 4 · accession 0001722024-18-000006
Evelo Biosciences, Inc. · EVLO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alexandria Venture Investments, LLC
10% Owner
Period of report
May 11, 2018
Accepted (ET)
May 21, 2018 · 4:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001694665
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 11, 2018 | C | 594,443 | — | A | 594,443 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A-3 preferred stockF2,F1 | — | May 11, 2018 | C | 416,650 | D | — | — | Common Stock | 102,145 | 0 | D |
| Series B preferred stockF2,F1 | — | May 11, 2018 | C | 1,388,889 | D | — | — | Common Stock | 340,497 | 0 | D |
| Series C preferred stockF2,F1 | — | May 11, 2018 | C | 619,195 | D | — | — | Common Stock | 151,801 | 0 | D |
Explanation of responses
- F1Each share of Series A-3, Series B and Series C preferred stock was convertible into the Issuer's common stock at a ratio of 4.079 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- F2Not applicable